• Meiji Holdings unit KM Biologics will supply LC16 mpox vaccine to a WHO-led global stockpile for emergency preparedness and outbreak response.
• The contract covers 192,500 doses; KM Biologics will donate another 57,500 doses to expand vaccine availability.
• KM Biologics and its parent, Meiji Seika Pharma, are pursuing WHO prequalification for LC16, which received WHO emergency-use listing in November 2024.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Meiji Holdings Co. Ltd. published the original content used to generate this news brief on October 28, 2026, and is solely responsible for the information contained therein.